Integrins: Roles in cancer development and as treatment targets

British Journal of Cancer

Volumn 90, Issue 3, 2004, Pages 561-565

  Jin, H ^a   Varner, J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Angiogenesis; Apoptosis; Integrin 5 1; Integrin v 3; Metastasis

Indexed keywords

BEVACIZUMAB; CILENGITIDE; INTEGRIN; MONOCLONAL ANTIBODY LM 609; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5 ANTIBODY;

ANGIOGENESIS; CANCER INVASION; CARCINOGENESIS; CELL DEATH; CELL MIGRATION; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; DISEASE COURSE; GLIOBLASTOMA; HUMAN; METASTASIS; MOLECULAR DYNAMICS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION;

CELL MOVEMENT; CELL SURVIVAL; DISEASE PROGRESSION; HUMANS; INTEGRINS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 1542269303     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601576     Document Type: Short Survey

References (56)

1. Aplin AE, Howe A, Alahari SK, Juliano RL (1998) Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules and selectins. Pharmacol Rev 50: 197-263
2. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967
3. Assoian RK, Schwartz MA (2001) Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 11: 48-53
4. Bader BL, Rayburn H, Crowley D, Hynes RO (1998) Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95: 507-519
5. Bakre MM, Zhu Y, Yin H, Burton DW, Terkeltaub R, Deftos LJ, Varner JA. (2002) Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med 8: 995-1003
6. Brooks PC, Clark RA, Cheresh DA (1994a) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571
7. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994b) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164
8. Boudreau N, Andrews C, Srebow A, Ravanpay A, Cheresh DA (1997) Induction of the angiogenic phenotype by Hox D3. J Cell Biol 139: 257-264
9. Boudreau N, Varner J (2003) The homeobox transcription factor Hox D3 promotes integrin α5β1 expression and function during angiogenesis. J Biol Chem, in press.
10. Boudreau N, Werb Z, Bissell MJ (1996) Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle. Proc Natl Acad Sci USA 93: 1353-3509
11. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL (2002) Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62: 4263-4272
12. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and disease. Nature 407: 249-257
13. Carron CP, Meyer DM, Pegg JA, Engleman VW, Nickols MA, Settle SL, Westlin WF, Ruminski PG, Nichols GA (1998) A peptidomimetic antagonist of the integrin αvβ3 inhibits Leydig cell tumor growth and development of hypercalcemia of malignancy. Cancer Res 58: 1930-1955
14. Cheresh D (1993) Integrins: structure, function and biological properties. Adv Mol Cell Biol 6: 225-252
15. Cheresh DA, Stupack DG (2002) Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med 8: 193-194
16. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT 2003)) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta5 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39: 917-926
17. Felding-Habermann B, Fransvea E, O'toole TE, Manzuk L, Faha B, Hensler M (2002) Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metast 19: 427-436
18. Fernando NH, Hurwitz HI (2003) Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 30: 39-50
19. Francis SE, Goh KL, Hodivala-Dilke K, Bader BL, Stark M, Davidson D, Hynes RO (2002) Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 22: 927-933
20. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270: 1500-1502
21. Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-626
22. Garzino-Demo P, Carrozzo M, Trusolino L, Savoia P, Gandolfo S, Marchisio PC (1998) Altered expression of alpha 6 integrin subunit in oral squamous cell carcinoma and oral potentially malignant lesions. Oral Oncol 34: 204-210
23. Gehlsen KR, Davis GE, Sriramarao P (1992) Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metast 10: 111-120
24. George EL, Baldwin HS, Hynes RO (1997) Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 90: 3073-3081
25. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO (1993) Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119: 1079-1091
26. Goh KL, Yang JT, Hynes RO (1997) Mesodermal defects and cranial neural crest apoptosis in α5 integrin-null embryos. Development 124: 4309-4319
27. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA (2000) Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6: 3056-3061
28. Hodivala-Dilke KM, Mchugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO (1999) β3-Integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 103: 229-238
29. Hood J, Cheresh D (2002) Role of integrins in cell invasion and migration. Nat Rev 2: 91-103
30. Huang X, Griffiths M, Wu J, Farese Jr. RV, Sheppard D (2000) Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice. Mol Cell Biol 20: 755-759
31. Hynes RO (1992) Integrins: versatility, modulation and signaling in cell adhesion. Cell 69: 11-25
32. Kerr JS, Slee AM, Mousa SA (2002) The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs 11: 1765-1774
33. Kim S, Bakre M, Yin H, Varner J (2002) Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 110: 933-941
34. Kim S, Bell K, Mousa SA, Varner J (2000a) Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell binding domain of fibronectin. Am J Path 156: 1345-1362
35. Kim S, Harris M, Varner JA (2000b) Regulation of integrin αvβ3-mediated endothelial cell migration and angiogenesis by integrin α5β1 and protein kinase A. J Biol Chem 275: 33920-33928
36. Mercurio AM, Bachelder RE, Chung J, O'Connor KL, Rabinovitz I, Shaw LM, Tani T (2001) Integrin laminin receptors and breast carcinoma progression. J Mammary Gland Biol Neoplasia 6: 299-309
37. Meredith Jr. JE, Fazeli B, Schwartz MA (1993) The extracellular matrix as a cell survival factor. Mol Biol Cell 4: 953-961
38. Mikecz K (2000) Vitaxin. Curr Opin Invest Drugs 1: 199-203
39. Nip J, Shibata H, Loskutoff DJ, Cheresh DA, Brodt P (1992) Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. J Clin Invest 90: 1406-1413
40. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. (2001) Pilot study of vitaxin - an angiogenesis inhibitor -in patients with advanced leiomyosarcomas. Cancer 92: 1347-1348
41. Pankov R, Cukierman E, Clark K, Matsumoto K, Hahn C, Poulin B, Yamada KM (2003) Specific beta1 integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A. J Biol Chem 278: 18671-18681
42. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF (2001) A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti alpha vbeta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16: 125-132
43. Ramos DM, But M, Regezi J, Schmidt BL, Atakilit A, Dang D, Ellis D, Jordan R, Li X (2002) Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol 21: 297-307
44. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM (2003) Alphavbeta3 integrin antagonist s247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 63: 2079-2087
45. Ren X-D, Kiosses WB, Schwartz MA (1999) Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J. 18: 578-585
46. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM (2002) Enhanced pathological angiogenesis in mice lacking β3 and β5integrins. Nat Med 8: 229-238
47. Schwartz MA, Shattil SJ (2000) Signaling networks linking integrins and Rho family GTPases. Tips 25: 388-391
48. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M (1997) Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci USA 94: 13612-13617
49. Smith JW (2003) Cilengitide Merck. Curr Opin Investig Drugs 4: 741-745
50. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM (2003) Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 20: 496-503
51. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA (1996) Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 98: 426-433
52. Stupack DG, Puente XS, Butsaboualoy S, Storgard CM, Cheresh DA (2001) Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 155: 459-470
53. Taverna D, Hynes RO (2001) Reduced blood vessel formation and tumor growth in alpha 5-integrin-negative teratocarcinomas and embryoid bodies. Cancer Res 61: 5255-5261
54. Yang JT, Rayburn H, Hynes RO (1993) Embryonic mesodermal defects in α5 integrin-deficient mice. Development 119: 1093-1105
55. Yang JT, Rayburn H, Hynes RO (1995) Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development Development 121: 549-560
56. Zhong J, Eliceiri B, Stupack D, Penta K, Sakamoto G, Hynes R, Coleman M, Quertermous T, Boudreau N, Varner J (2003) Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Dell. J Clin Invest 112: 30-41